Pionyr (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the third generation of immuno-oncology therapeutics after checkpoint inhibitors and CAR-T. The company's approach, Myeloid Tuning™, is designed to enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/17 | $8,000,000 | Series A-1 |
Mission Bay Capital OrbiMed Advisors Osage University Partners | undisclosed |
| 12/14/17 | $62,000,000 | Series B |
Mission Bay Capital OrbiMed Advisors Osage University Partners Sofinnova Ventures SV Health Investors Vida Ventures | undisclosed |
